logo_bg We Can Cure Alzheimer's Now
 
 

First-of-its-Kind Alzheimer's Disease Study in Orlando & The Villages Seeks Volunteers

ORLANDO, Fla., Nov. 5, 2015 /PRNewswire/ -- More than 5 million Americans—including 500,000 Floridians—are currently suffering from Alzheimer's disease, and scientists expect this number to nearly triple by 2050. And, experts say that minority communities, including African Americans and Hispanics are more likely than white Americans to develop the disease.

A groundbreaking study, being conducted by local researchers at Compass Research in Orlando and The Villages, is testing whether an investigational drug can prevent or slow the development of Alzheimer's. Researchers seek volunteers who have just the earliest changes in their brain associated with the disease, but don't yet have any symptoms. The A4 study is a landmark public-private partnership, funded by the National Institute on Aging (NIH), Eli Lilly and Company, and several other philanthropic organizations. The study is coordinated by the Alzheimer's disease Cooperative Study, located at the University of California, San Diego and is led by world-renowned neurologist Reisa Sperling, MD, of Brigham and Women's Hospital and Harvard Medical School.

The A4 Study (which stands for the Anti-Amyloid in Asymptomatic Alzheimer's study) seeks to delay Alzheimer's-related brain damage and curb memory loss before any outward signs develop. Healthy people with normal memories are needed to join the clinical trial aiming to prevent memory loss associated with the disease.

 

"It is extremely important that members of our community get involved with this study," said Dr. Craig Curtis, Chief Medical Officer of Compass Research. "For the first time, the A4 Study offers new hope—a chance for people to fight back, giving them something they can actively do to protect their own and their family's memories."

Use this link to view the original version on PR Newswire.